MET and cancer: These upregulated promoters encode for novel isoforms of receptor tyrosine kinases that are activated in diverse cancer types, such as MET, FGFR4, and ERBB3. Interestingly, in all three cases, the choice of alternate promoters abolishes the N-terminal signal peptide required for targeting to cellular membrane in all three novel isoforms.